View ValuationEurofins Scientific 将来の成長Future 基準チェック /16Eurofins Scientific利益と収益がそれぞれ年間17.5%と5.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.6% 17.4%なると予測されています。主要情報17.5%収益成長率17.42%EPS成長率Life Sciences 収益成長17.1%収益成長率5.9%将来の株主資本利益率14.61%アナリストカバレッジGood最終更新日22 Jun 2026今後の成長に関する最新情報お知らせ • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.お知らせ • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.お知らせ • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.すべての更新を表示Recent updatesお知らせ • Mar 24Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026, at 16:30 W. Europe Standard Time. Location: 2 4 rue d arlon, windhof Luxembourgお知らせ • Feb 10Eurofins Viracor BioPharma Expands Bioanalytical CapabilitiesEurofins Viracor BioPharma Services announced a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor Bio Pharma's purpose-built, eleven-acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories' strengths, Eurofins ViracorBioPharma expands the depth of scientific expertise available to sponsors while simplifying access to integrated technologies, harmonized contracting, and comprehensive testing solutions under one unit; providing sponsors with more seamless and efficient experience. The newly expanded laboratory space in Lenexa was meticulously designed to meet the needs of increasingly complex clinical trials, ensuring high-quality sample management, streamlined workflows, and robust data integrity. With these enhanced capabilities, Eurofins Virac or BioPharma now offers a full suite of bioanalytical services, including method development, validation, and regulated sample analysis, all consistent with global regulatory guidance.お知らせ • Jan 29Eurofins Scientific SE Proposes Annual DividendEurofins Scientific SE announced that at the upcoming Annual General Meeting on 23 April 2026, the Board of Directors intends to propose an annual dividend of €0.72 per share, which is a year-on-year increase of 20%, and is in line with growth in Basic EPS8 attributable to owners of the Company. This payout would represent a split-adjusted 27% CAGR in the dividend per share, since Eurofins’ first dividend was declared for 2007.お知らせ • Jan 26Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening SoftwareEurofins CDMO Alphora announced the development and launch of a new AI-powered software for high throughput salt and co-crystal screening - now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates. This breakthrough technology streamlines solid form selection by minimizing trial and error experimentation, shortening development timelines, and lowering screening costs. With a user-friendly interface and advanced predictive models, the tool empowers clients to make smarter, data-driven decisions earlier in the drug substance development process --resulting in faster, more efficient delivery of optimized solid forms. Eurofins CDMO ALora's seasoned Solid-State R&D team guides partners and customers through every stage of salt and co-cry crystal development--from data interpretation to experimental strategy. Beyond salt and co-crystal work, the team is well positioned to address a full spectrum of solid-state challenges. Through close cross-departmental collaboration with drug product and drug substance development teams, Eurofins CDMO Alphore delivers fully integrated solutions to improve therapeutic bioavailability and manufacturing processing.お知らせ • Dec 23Eurofins Scientific SE to Report Fiscal Year 2025 Results on Jan 29, 2026Eurofins Scientific SE announced that they will report fiscal year 2025 results on Jan 29, 2026お知らせ • Dec 02Eurofins Medical Device Services North America Launches First GMP Pfas Screening and Testing Solutions for Medical DevicesEurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety. Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices. Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.お知らせ • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.お知らせ • May 21Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others.Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others on May 20, 2025. The Kiel site will not only remain intact it will even be expanded. The newly constructed laboratory building and the entire experienced Planton team will form the foundation for further growth under the Eurofins umbrella. Andreas Masuch of MELCHERS Rechtsanwälte acted as legal advisor and Consus Partner acted as financial advisor for PLANTON GmbH. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of PLANTON GmbH from Michael Kleine and others on May 20, 2025.お知らせ • Apr 25Eurofins Scientific SE Proposes Annual Dividend, Payable on April 30, 2025Eurofins Scientific SE's Board of Directors proposed annual dividend of €0.60 per share, subject to approval at the upcoming Annual General Meeting on 24 April 2025 and payable on 30 April 2025.お知らせ • Apr 01Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on March 31, 2025. With this acquisition, Eurofins will become a leading clinical diagnostics operator in Spain, with a unique capability to cater to public and private clients and cover all regions in the country.お知らせ • Mar 26Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025.お知らせ • Dec 28Eurofins Scientific SE to Report Fiscal Year 2024 Results on Jan 30, 2025Eurofins Scientific SE announced that they will report fiscal year 2024 results on Jan 30, 2025お知らせ • Nov 09Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025Eurofins Scientific SE announced that they will report first half, 2025 results on Jul 24, 2025お知らせ • Oct 28Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025.お知らせ • Sep 17Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024.お知らせ • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.お知らせ • Apr 03Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC on April 3, 2024. Patti Hunsader, the current chief operating officer of Ascend, will assume the role of President of Ascend Clinical. The existing leadership of the company will remain in place, continuing to drive the organization's growth as part of the Eurofins clinical diagnostics business line in the United States. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Ascend Clinical, LLC on April 3, 2024.お知らせ • Mar 25Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024, at 16:30 Central European Standard Time. Location: 2-4 Rue d’Arlon L-8399 Windhof Grand Duchy Of Luxemboug Luxembourg Agenda: To review of the management report prepared by the board of directors, including the group management report, the special report on the conflicts of interest and the special report on the buy-back of its own shares for the financial year ended 31 December 2023; to review of the special report on the transactions carried-out in the context of the authorized share capital; to review the report of the approved statutory auditor on the annual statutory accounts prepared in accordance with the laws and regulations of the Grand Duchy of Luxembourg, the consolidated financial statements prepared in accordance with the IFRS for the financial year ended 31 December 2023, and on the performance of its mission; to approve the consolidated financial statements and the annual statutory accounts for the financial year ended 31 December 2023; ; to approve the allocation of net profit for the financial year ended 31 December 2023; and to consider other matters.お知らせ • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.お知らせ • Jun 09Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023Eurofins Scientific SE announced that they will report first half, 2023 results on Jul 26, 2023お知らせ • Oct 04Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023Eurofins Scientific SE announced that they will report fiscal year 2022 results on Feb 21, 2023業績と収益の成長予測OTCPK:ERFS.F - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20288,6587969701,6881112/31/20278,0676768801,6171212/31/20267,5955177201,3711112/31/20257,2964165641,399N/A9/30/20257,2203996741,357N/A6/30/20257,1443817841,315N/A3/31/20257,0483697871,317N/A12/31/20246,9513567911,319N/A9/30/20246,8373417321,267N/A6/30/20246,7243266741,215N/A3/31/20246,6192915711,117N/A12/31/20236,5152574681,018N/A9/30/20236,512335403995N/A6/30/20236,510414339971N/A3/31/20236,6114974071,054N/A12/31/20226,7125814761,136N/A9/30/20226,7856126021,219N/A6/30/20226,8576437271,301N/A3/31/20226,7876968661,406N/A12/31/20216,7187491,0051,511N/A9/30/20216,5537861,0231,499N/A6/30/20216,3888241,0411,487N/A3/31/20215,9136659551,355N/A12/31/20205,4395058681,224N/A9/30/20205,0793477131,057N/A6/30/20204,719190558891N/A3/31/20204,641168457784N/A12/31/20194,563146355678N/A9/30/20194,384144N/A618N/A6/30/20194,205143N/A558N/A3/31/20193,993159N/A551N/A12/31/20183,781175N/A544N/A9/30/20183,549182N/A521N/A6/30/20183,318190N/A498N/A3/31/20183,145185N/A451N/A12/31/20172,971179N/A405N/A9/30/20172,848166N/A387N/A6/30/20172,725152N/A369N/A3/31/20172,631145N/A370N/A12/31/20162,537138N/A372N/A9/30/20162,427104N/A350N/A6/30/20162,31769N/A328N/A3/31/20162,13363N/A310N/A12/31/20151,95056N/A291N/A9/30/20151,77971N/A274N/A6/30/20151,60986N/A256N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ERFS.Fの予測収益成長率 (年間17.5% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: ERFS.Fの収益 ( 17.5% ) US市場 ( 18.9% ) よりも低い成長が予測されています。高成長収益: ERFS.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: ERFS.Fの収益 ( 5.9% ) US市場 ( 13% ) よりも低い成長が予測されています。高い収益成長: ERFS.Fの収益 ( 5.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ERFS.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 14.6 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 22:54終値2026/06/23 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Eurofins Scientific SE 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31 アナリスト機関James Rowland ClarkBarclaysJames RosenthalBarclaysCarl RaynsfordBerenberg28 その他のアナリストを表示
お知らせ • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.
お知らせ • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.
お知らせ • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.
お知らせ • Mar 24Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026Eurofins Scientific SE, Annual General Meeting, Apr 23, 2026, at 16:30 W. Europe Standard Time. Location: 2 4 rue d arlon, windhof Luxembourg
お知らせ • Feb 10Eurofins Viracor BioPharma Expands Bioanalytical CapabilitiesEurofins Viracor BioPharma Services announced a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor Bio Pharma's purpose-built, eleven-acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories' strengths, Eurofins ViracorBioPharma expands the depth of scientific expertise available to sponsors while simplifying access to integrated technologies, harmonized contracting, and comprehensive testing solutions under one unit; providing sponsors with more seamless and efficient experience. The newly expanded laboratory space in Lenexa was meticulously designed to meet the needs of increasingly complex clinical trials, ensuring high-quality sample management, streamlined workflows, and robust data integrity. With these enhanced capabilities, Eurofins Virac or BioPharma now offers a full suite of bioanalytical services, including method development, validation, and regulated sample analysis, all consistent with global regulatory guidance.
お知らせ • Jan 29Eurofins Scientific SE Proposes Annual DividendEurofins Scientific SE announced that at the upcoming Annual General Meeting on 23 April 2026, the Board of Directors intends to propose an annual dividend of €0.72 per share, which is a year-on-year increase of 20%, and is in line with growth in Basic EPS8 attributable to owners of the Company. This payout would represent a split-adjusted 27% CAGR in the dividend per share, since Eurofins’ first dividend was declared for 2007.
お知らせ • Jan 26Eurofins CDMO Alphora Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening SoftwareEurofins CDMO Alphora announced the development and launch of a new AI-powered software for high throughput salt and co-crystal screening - now a core component of all solid-state screening programs. Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates. This breakthrough technology streamlines solid form selection by minimizing trial and error experimentation, shortening development timelines, and lowering screening costs. With a user-friendly interface and advanced predictive models, the tool empowers clients to make smarter, data-driven decisions earlier in the drug substance development process --resulting in faster, more efficient delivery of optimized solid forms. Eurofins CDMO ALora's seasoned Solid-State R&D team guides partners and customers through every stage of salt and co-cry crystal development--from data interpretation to experimental strategy. Beyond salt and co-crystal work, the team is well positioned to address a full spectrum of solid-state challenges. Through close cross-departmental collaboration with drug product and drug substance development teams, Eurofins CDMO Alphore delivers fully integrated solutions to improve therapeutic bioavailability and manufacturing processing.
お知らせ • Dec 23Eurofins Scientific SE to Report Fiscal Year 2025 Results on Jan 29, 2026Eurofins Scientific SE announced that they will report fiscal year 2025 results on Jan 29, 2026
お知らせ • Dec 02Eurofins Medical Device Services North America Launches First GMP Pfas Screening and Testing Solutions for Medical DevicesEurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety. Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices. Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.
お知らせ • Jul 23Eurofins Scientific SE Provides Earnings Guidance for Fiscal Year 2025 and for the Mid-Term to Fiscal Year 2027Eurofins Scientific SE provided earnings guidance for fiscal year 2025 and for the mid-term to fiscal year 2027. For 2025, the company targets mid-single-digit organic growth and potential revenues from acquisitions of €250 million consolidated at mid-year. For mid-term to fiscal year 2027, the company confirms its long-term average organic growth objective of 6.5% p.a. driven by secular growth trends in its end markets as well as its target for potential average revenues from acquisitions of €250 million p.a. over the period consolidated at mid-year.
お知らせ • May 21Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others.Eurofins Scientific SE (ENXTPA:ERF) acquired PLANTON GmbH from Michael Kleine and others on May 20, 2025. The Kiel site will not only remain intact it will even be expanded. The newly constructed laboratory building and the entire experienced Planton team will form the foundation for further growth under the Eurofins umbrella. Andreas Masuch of MELCHERS Rechtsanwälte acted as legal advisor and Consus Partner acted as financial advisor for PLANTON GmbH. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of PLANTON GmbH from Michael Kleine and others on May 20, 2025.
お知らせ • Apr 25Eurofins Scientific SE Proposes Annual Dividend, Payable on April 30, 2025Eurofins Scientific SE's Board of Directors proposed annual dividend of €0.60 per share, subject to approval at the upcoming Annual General Meeting on 24 April 2025 and payable on 30 April 2025.
お知らせ • Apr 01Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on March 31, 2025. With this acquisition, Eurofins will become a leading clinical diagnostics operator in Spain, with a unique capability to cater to public and private clients and cover all regions in the country.
お知らせ • Mar 26Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025Eurofins Scientific SE, Annual General Meeting, Apr 24, 2025.
お知らせ • Dec 28Eurofins Scientific SE to Report Fiscal Year 2024 Results on Jan 30, 2025Eurofins Scientific SE announced that they will report fiscal year 2024 results on Jan 30, 2025
お知らせ • Nov 09Eurofins Scientific SE to Report First Half, 2025 Results on Jul 24, 2025Eurofins Scientific SE announced that they will report first half, 2025 results on Jul 24, 2025
お知らせ • Oct 28Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB).Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire clinical diagnostics operations in Spain from SYNLAB AG (HMSE:SYAB) on October 28, 2024. For the period ending December 31, 2023, clinical diagnostics operations in Spain of SYNLAB AG reported total revenue of €140 million. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025.
お知らせ • Sep 17Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited.Eurofins Scientific SE (ENXTPA:ERF) acquired Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Infinity Laboratories, LLC from Imperial Capital Acquisition Fund VI and Imperial Capital Limited on September 16, 2024.
お知らせ • Jul 24Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2024Eurofins Scientific SE provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the range of €7.075 billion to €7.175 billion.
お知らせ • Apr 03Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC on April 3, 2024. Patti Hunsader, the current chief operating officer of Ascend, will assume the role of President of Ascend Clinical. The existing leadership of the company will remain in place, continuing to drive the organization's growth as part of the Eurofins clinical diagnostics business line in the United States. Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Ascend Clinical, LLC on April 3, 2024.
お知らせ • Mar 25Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024, at 16:30 Central European Standard Time. Location: 2-4 Rue d’Arlon L-8399 Windhof Grand Duchy Of Luxemboug Luxembourg Agenda: To review of the management report prepared by the board of directors, including the group management report, the special report on the conflicts of interest and the special report on the buy-back of its own shares for the financial year ended 31 December 2023; to review of the special report on the transactions carried-out in the context of the authorized share capital; to review the report of the approved statutory auditor on the annual statutory accounts prepared in accordance with the laws and regulations of the Grand Duchy of Luxembourg, the consolidated financial statements prepared in accordance with the IFRS for the financial year ended 31 December 2023, and on the performance of its mission; to approve the consolidated financial statements and the annual statutory accounts for the financial year ended 31 December 2023; ; to approve the allocation of net profit for the financial year ended 31 December 2023; and to consider other matters.
お知らせ • Jul 26Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027Eurofins Scientific SE has updated its objectives for Fiscal year 2023 and guidance for 2027. For the year, company expects Revenues to be €6.45 billion – €6.55 billion. For fiscal year, company expects Revenues to be Approaching €10 billion. The objectives for Fiscal Year 2027 have not been updated.
お知らせ • Jun 09Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023Eurofins Scientific SE announced that they will report first half, 2023 results on Jul 26, 2023
お知らせ • Oct 04Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023Eurofins Scientific SE announced that they will report fiscal year 2022 results on Feb 21, 2023